Abstract: A composite comprising electrospun inorganic fibers and nanoparticles. The composite may carry a reagent, for example an oxidant. The composite may be formed by electro spinning a composition of a precursor material and nanoparticles to form a precursor composite followed by conversion of precursor fibers of the precursor composite to the inorganic fibers. The composite carrying a reagent may be used to absorb ethylene gas.
Type:
Application
Filed:
December 30, 2017
Publication date:
April 29, 2021
Applicant:
University of Cincinnati
Inventors:
Andrew Steckl, Daewoo Han, Ashkan Tirgar
Abstract: A tandem electrode for electrochemically reducing carbon dioxide is described. The electrode includes a first distinct catalyst layer and a second distinct catalyst layer. The first distinct catalyst layer is made of a C1 hydrocarbon or C2+ product selective catalyst and the second distinct catalyst layer is comprised of a CO selective catalyst. In one embodiment, the second distinct catalyst layer is concentrated at one end of the tandem electrode. In another embodiment, the tandem electrode also includes a microporous layer and a substrate layer.
Abstract: The present invention relates generally to compositions and methods of killing biofilm using a surface plasmon coupled to a photosensitizer. A nanostructure (10) may include a silver nanoparticle core (12), a mesoporous silica shell (14), and a photosensitizer (16). A method of killing biofilm may include contacting biofilm with a nanostructure (10) including a silver nanoparticle core (12), a mesoporous silica shell (14), and a photosensitizer (16) to form a blend and exposing the blend to light.
Type:
Grant
Filed:
September 20, 2019
Date of Patent:
April 6, 2021
Assignee:
University Of Cincinnati
Inventors:
Peng Zhang, Rebecca Nogueira e Silva, Hong Tang
Abstract: A device (10) for directing a medical fabric (28) into a portion of a body. An elongated housing (12) having a distal end (16) and an opening (22) at the distal end (16). A supply of medical fabric (28) in the housing (12). An actuator (24) spaced from said opening (22) and configured to advance a portion of the medical fabric (28) through said housing (12) and out of the opening (22).
Abstract: Methods for the treatment of cardiac hypertrophy are described. Additionally, the presently disclosed subject matter relates to the use of small molecule compounds for the inhibition of Human antigen R (HuR)-mRNA interaction, and more particularly for the reduction of nuclear factor of activated T cells (NFAT) transcriptional activity. Novel methods of screening for small molecule compounds for inhibition of RNA binding proteins interaction with their target RNA (such as HuR-mRNA interactions) or for inhibition of DNA binding proteins to their target DNA are also described.
Type:
Grant
Filed:
April 5, 2017
Date of Patent:
March 2, 2021
Assignee:
University of Cincinnati
Inventors:
Michael Tranter, Sarah Anthony, Samuel Slone
Abstract: A sweat sensor device (200) includes one or more sweat sensors (220) and a seal (280) covering the one or more sweat sensors (220). The seal (280) is adapted to protect the sweat sensors (220) from outside contaminants when the device (200) is placed on the skin (12). The sweat sensor device (200) may include an absorbing medium (230) to absorb sweat from the skin (12) that is covered by the seal (280). The seal (280) can be permeable to gas, permeable to water and impermeable to at least one aqueous solute, or selectively permeable to at least one aqueous solute. The sweat sensor device (200) may include an artificial sweat stimulation mechanism (345) for stimulating sweat when the device (200) is placed on the skin (12).
Abstract: Described are sensors and methods of detecting hydrogen gas. The sensor includes a polymer matrix and a dye molecule in an amount sufficient such that exposure of the polymer matrix to hydrogen gas causes a change in a spectroscopic property of the dye molecule wherein the spectroscopic property includes at least one of color, absorbance, or luminescence. The polymer matrix may further include a catalyst, such as a transition metal, sulfonated Wilkinson's catalyst, colloidal Pt, sulfonated iridium cyclooctadiene triphenylphosphine, sulfonated rhodium cyclooctadiene triphenylphosphine, sulfonated ruthenium triphenylphosphine, or combinations thereof. Embodiments of the sensor may further include a gas permeable, water impermeable membrane, an outer covering, or combinations thereof.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
March 2, 2021
Assignee:
University of Cincinnati
Inventors:
William R. Heineman, John A. Lynch, Daniel P. Rose, Julia Kuhlmann, Daoli Zhao, Peng Zhang, Michael E. Smith
Abstract: Disclosed are kits and methods for determining the presence or absence of an antibody of interest in a biological sample of a subject. In particular, the methods may detect either pathological or beneficial antibodies. The method may include the step of contacting a biological sample from a subject with a substrate conjugated to an antigen and an Fc receptor operatively linked to a detectable label. Detection of the label may indicate the presence or absence of an antibody of interest.
Abstract: Devices that sense sweat and are capable of providing chronological assurance are described. The device uses at least one sensor to measure sweat or its components and to determine a sweat sampling rate. The chronological assurance is determined, at least in part, using the sweat sampling rate. The sweat sampling rate may be determined, at least in part, using a sweat volume and/or a sweat generation rate, both of which may be measured or predetermined.
Abstract: Methods of treating a psychiatric disorder in a subject are provided which include placing at least one anode on an area of the subject's back over the dorsal spinal cord at the level of one or more of: thoracic vertebra 7 (T7), 8 (T8), 9 (T9), 10 (T10), 11 (T11), and 12 (T12) and lumbar vertebra 1 (L1); placing at least one cathode on an area of the subject's back which is generally rostral with reference to the anode; connecting the anode and the cathode to at least one source of direct and/or alternating electrical current; delivering direct current to the anode for a treatment period of time, the treatment period of time defining a tsDCS and/or tsACS treatment session, thereby modulating spinal input to the brain of the subject, decreasing sympathetic activity and reducing one or more symptoms and/or comorbidities associated with the psychiatric disorder.
Abstract: Systems and methods of use and fabrication are described for a non-volatile resistive random access memory (RRAM) multi-terminal device including a first electrode, a second electrode, a metal oxide disposed between the first electrode and the second electrode, and an at least first gate configured to apply a voltage bias to change a resistive state in the metal oxide.
Abstract: Non-invasive electroencephalogram (EEG)-based methods for detecting a spreading depolarization secondary to a brain injury in a patient who exhibits high-amplitude delta activity in at least one channel of a scalp EEG of an injured brain hemisphere of the patient include (a) recording a baseline scalp EEG pattern in the patient at a channel exhibiting high amplitude delta activity; (b) recording a continuous scalp EEG pattern in the patient across a time frame at the at least one channel; and (c) detecting a spreading depolarization during the time frame by observing at least one feature indicative of a spreading depolarization in the continuous scalp EEG recording pattern relative to the baseline scalp EEG pattern at the at least one channel. Scalp EEG recordings are time-compressed prior to analysis. Methods of treating brain-injured patients and triaging brain-injured patients apply the non-invasive EEG methods.
Type:
Grant
Filed:
June 30, 2015
Date of Patent:
December 1, 2020
Assignee:
University of Cincinnati
Inventors:
Jed A. Hartings, J. Adam Wilson, Jason M. Hinzman, Norberto Andaluz, Vincent DiNapoli, Sebastian Pollandt
Abstract: A vascular implant device configured to decrease turbulence in blood flow through an arteriovenous fistula is described. The implant includes an arterial section having a straight hollow tube, a venous section having a curved hollow tube divided into an orthogonal portion at the juncture of the arterial section, a curved portion, and a straight extension portion, and having a continual lumen and lumen surface. The curved portion curves approximately 90 degrees with respect to the arterial section, and the extension portion extends substantially parallel to the arterial section. A plurality of flow-conditioning tabs are located along the lumen surface in arrangements precisely designed to convert the turbulent blood flow that enters the venous section into substantially laminar flow, and to minimize oscillatory shear stress on the venous endothelium as the blood flow exits the device and enters the vein.
Type:
Grant
Filed:
August 29, 2016
Date of Patent:
December 1, 2020
Assignee:
University of Cincinnati
Inventors:
Keith Louis Saum, Prabir Roy-Chaudhury, Begona Campos-Naciff, Diego Celdran-Bonafonte
Abstract: A laminate which can serve as either a smart window or a smart mirror is formed using first and second substrates coated with transparent first and second electrodes which are separated by foraminous layer and a third grid-like linear electrode insulated from the first and second electrodes. The foraminous layer includes spacers defining a cell space which is filled with a colloidal ink having first and second particles. The first particles have a positive charge and a first color and second particles having a negative charge and a second color different from the first color. By altering the voltages of the first, second and third electrodes, one can achieve different light transmission characteristics which, for example, can alter the color temperature of the light transmitted through the laminate or enhance reflective colors.
Type:
Grant
Filed:
December 2, 2015
Date of Patent:
December 1, 2020
Assignees:
University of Cincinnati, Crown Electrokinetics Corp.
Inventors:
Tim R. Koch, Jason C. Heikenfeld, Sayantika Mukherjee
Abstract: Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC1 or upstream or downstream pathway components of S6K1 or mTORC1, in association with administration of at least one inhibitor of PPAR?, PPAR?, or PGC1?. In various embodiments, the compound that inhibits S6K1, mTORC1, or upstream or downstream pathway components of S6K1 or mTORC1 is rapamycin, everolimus, temsirolimus, or imatinib. The inhibitor of PPAR?, PPAR?, or PGC1? can be an antagonist or an inverse agonist selected from GW6471, GSK3787, GSK0660, and ST247.
Abstract: A sensor for isolating, identifying, and quantifying one or more analytes in a sample is provided. Also provided are methods of isolating, identifying, and quantifying one or more analytes in a sample, the method including contacting a polymer waveguide with a sample, sequentially heating the polymer waveguide to a plurality of temperature thresholds, obtaining an optical output at each temperature threshold, and analyzing differences in sequentially-obtained optical outputs in order to identify and determine concentrations of individual analytes of interest in the sample.
Type:
Grant
Filed:
August 18, 2016
Date of Patent:
November 3, 2020
Assignee:
University of Cincinnati
Inventors:
Fred R. Beyette, Jr., Geethanga Gayan De Silva
Abstract: Described are inventions directed to methods of treating a cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof. In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years.
Abstract: Pharmaceutical compositions of selective EP2 antagonists exemplified by small molecules TG4-155 and TG6-10-1 effective for treating gliomas, and methods for administering the pharmaceutical compositions to treat subjects suffering from disorders characterized by gliomagenesis.